Now in its twelfth year, Class 46 is dedicated to European trade mark law and practice. This weblog is written by a team of enthusiasts who want to spread the word and share their thoughts with others.
Click here subscribe for free.
Who we all are...
General Court: Biocert v Biocef
In case T-605/11, the General Court dealt with the
following opposition
Dr Organic
Ltd |
Novartis |
BIOCERT |
BIOCEF |
Dietary
substances and preparations; medicinal health care products; food supplements
for dietetic use; nutritional supplements for human beings; vitamins;
minerals (nutritional supplements); amino acids (nutritional supplements);
plants and herbs for medical or veterinary purposes; herbal preparations for
medicinal use; animal and plant extracts, including oils, for medical or
veterinary purposes; chemical preparations for medical or veterinary use;
naturopathic and homeopathic preparations; tonics; mineral food additives;
mineral drinks; vitamin drinks; nutrients and nutriments; medical sprays,
patches and other topical formulations; medicated skin care preparations;
pharmaceutical preparations and substances; anti-rheumatism belts; bandages,
plasters, dressings and wraps; massage and body wraps; oxygen baths; mud for
baths; medicinal mud; medicinal oils; thermal water; mineral water salts; eye
washes; medicated mouthwashes; slimming preparations; antiseptics;
disinfectants; detergents for medical purposes; sanitary preparations; liquid
food supplements’ in Class 5 |
‘pharmaceutical preparations’ in Class 5 |
OHIM, as confirmed by the GC, found that the goods covered by the marks are
either identical or similar; the relevant public is made up of professionals
from the medical and pharmaceutical fields and general end consumers in
Austria, who demonstrate a heightened degree of attentiveness as regards
pharmaceuticals; the two marks contain the word ‘bio’, a common
abbreviation in German of the word ‘biological’ and thus having a descriptive
meaning. Consumers’ attention accordingly focuses on the elements ‘cert’ and
‘cef’. Being a descriptive element, ‘bio’ is insufficient for establishing a
conceptual similarity between the marks at issue; in view of the average
distinctiveness of the BIOCEF mark, the low visual and phonetic similarities
between the signs at issue and the heightened degree of attentiveness of the
relevant public, there is no likelihood of confusion, even in respect of
identical goods.
The General Court annulled the decision
of the 4th BoA, recalling first that the assessment of the
similarity between two marks cannot be confined to taking one sole component of
a complex mark and comparing it with another mark, but that a comparison must
be carried out wherein each of the marks in question is examined as a whole.
Furthermore, finding of a likelihood of confusion in the present case would not
grant the applicant a monopoly on the element ‘bio’, given that the existence
of a likelihood of confusion leads solely to the protection of a certain
combination of elements without, however, protecting as such a descriptive
element forming part of that combination (see Industrias Alen v The Clorox Company)
the visual and phonetic similarities
between the marks at issue do not arise only from the presence of the element
‘bio’ in the marks at issue, but also from the almost identical length of the
signs and the fact that their first five letters match. In addition, the same
letters appear in the initial part of each of those marks.
Thus, given the identical or similar
nature of the products, the average degree of distinctiveness of the earlier
mark as a whole, it is must be held that there is a likelihood of confusion
between the marks at issue, even if the public has an heightened level of
attention.
Tags: General Court, biocert, biocef, pharmaceutical ,



Perm-A-Link: https://www.marques.org/blogs/class46?XID=BHA3955